Tracy M Downs

Professor
Bladder Cancer and Intravesical Therapy Programs
University of Wisconsin
United States of America

Academician Nephrology
Biography

Education Dr. Downs did his MD from University of California-San Diego, La Jolla, CA, 1993. He did his Internship, Brigham and Women’s Hospital (Harvard), Boston, MA, 1995. He is Clinical Nutrition Fellowship from Harvard, Boston, MA, 1999. He is Resident of Brigham and Women’s Hospital (Harvard), Boston, MA, 2001. He got Research Fellowship from University of California-San Francisco, San Francisco, CA, 2003. He got Urologic Oncology Fellowship from University of California-San Francisco, San Francisco, CA, 2003. Clinical Specialties Dr. Downs is certified by the American Board of Urology. He specializes in the surgical treatment of urologic cancers and treats all forms of urologic cancers including bladder cancer, prostate cancer, kidney cancer, testis cancer and penile cancer. He has a special interest in the treatment of bladder cancer, where he performs robotic cystectomy (da Vinci robotic system), along with complex urinary reconstruction to make a new internalized bladder (orthotopic neobladder). Dr. Downs’ clinical care philosophy is to provide compassionate, cutting-edge urologic cancer care to his patients.

Research Intrest

Dr. Downs has a joint appointment with the UW Carbone Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers.

List of Publications
Tazeh NN, Canter DJ, Damodaran S, Rushmer T, Richards KA, Abel EJ, Jarrard DF, Downs TM. Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences. Bladder Cancer 2017 Apr 27; 3(2):89-94. [PubMed ID: 28516153, PMCID: 5409044]
Blute ML, Kucherov V, Rushmer TJ, Damodaran S, Shi F, Abel EJ, Jarrard DF, Richards KA, Messing EM, Downs TM. Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m(2) ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int. 2017 May 02. [PubMed ID: 28464520]
Wang JH, Downs TM, Jason Abel E, Richards KA, Jarrard DF. Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies. Curr Urol Rep 2017 Jul; 18(7):48. [PubMed ID: 28589399]